Business
Capricor Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
Duchenne Muscular Dystrophy Program-Final Top-Line 12-month Results from Phase II Randomized, Double-blind, Placebo-controlled HOPE-2- Study Demonstrated
About this update from Capricor Therapeutics, Inc.
[{"type":"text","content":"Duchenne Muscular Dystrophy Program-Final Top-Line 12-month Results from Phase II Randomized, Double-blind, Placebo-controlled HOPE-2- Study Demonstrated Improved Performance of Upper Limb (PUL) 2.0 (p=0.05)-\n COVID-19 Program -COVID-19 Compassionate Use Case Series Published in Peer Reviewed Journal- -Reported 100 Percent Survival in Critical COVID-19 Patients Treated with CAP-1002 Under Compassionate Use Pathway- -Expanded Access Protocol Approved by FDA to Treat Critical COVID-19 Patients- -Appointed Stephen J. Gould, Ph.D. to lead Capricor’s Exosome-Based Platform Vaccine Approach Against COVID-19- -To Host Conference Call and Webcast Today at 4:30 p.m. ET- LOS ANGELES, May 14, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor”) (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment and prevention of diseases, announced today its financial results for the first quarter 2020 and provided a recent corporate update. “The first quarter of 2020 has been incredibly productive on so many levels and I am pleased that we have been able to advance our pipeline during these challenging times. As we have described, CAP-1002, our lead product candidate, has strong immunomodulatory characteristics and has been shown preclinically to address some of the same pathology caused by COVID-19. We were very quick to institute a compassionate use program where CAP-1002 was used to treat six patients with COVID-19 which led to the publication of a peer-reviewed paper. Based on that encouraging data, we filed and now have an approved IND for an expanded access program to treat up to 20 additional patients,” said Linda Marbán, Ph.D., Capricor’s president and chief executive officer. Capricor also remains diligently focused on the treatment of DMD using CAP-1002. Capricor continues to advance CAP-1002 for the treatment of DMD with the positive 12-month data announced earlier this week showing improvements in upper limb, cardiac and respiratory function. The 12-month data from the HOPE-2 trial showed statistically meaningful improvements in the PUL 2.0 in CAP-1002 treated patients (p=0.05) with a mean change of 2.4 points over placebo patients. The FDA has suggested the use of the updated PUL 2.0 version as the primary efficacy endpoint in support of a Biolo...